title: [Reactivation of hepatitis B virus due to rituximab plus CHOP after preemptive lamivudine administration in a patient with diffuse large B-cell lymphoma].
abstract: A 59-year-old woman received eight cycles of R-CHOP for diffuse large B-cell lymphoma from July, 2004. Pretreatment HBV serological tests were positive, however, the transaminases were within normal limits, and she remained asymptomatic. Lamivudine (LAM) was administered orally from the start of R-CHOP. HBV-DNA levels gradually decreased and were not detected until December, 2004. LAM was administered until 3 months after the end of chemotherapy, with the entire treatment lasting less than 1 year. Two months after the cessation of treatment, she was re-admitted for general malaise. A liver function test revealed severe abnormalities, and HBVDNA levels were increased. Clinically, she was experiencing acute hepatitis due to HBV reactivation. She was then treated with LAM and interferon-beta immediately. Her HBV-DNA levels soon decreased, and liver function improved.
authors: Fourth Department of Internal Medicine, Sapporo Medical University School of Medicine.
authors: Kaoru
authors: K
authors: Ono
authors: Satoshi
authors: S
authors: Iyama
authors: Takuya
authors: T
authors: Matsunaga
authors: Tsutomu
authors: T
authors: Sato
authors: Yasushi
authors: Y
authors: Sato
authors: Toshinori
authors: T
authors: Okuda
authors: Kohichi
authors: K
authors: Takada
authors: Yutaka
authors: Y
authors: Kawano
authors: Tsuyoshi
authors: T
authors: Hayashi
authors: Koji
authors: K
authors: Miyanishi
authors: Tamotsu
authors: T
authors: Sagawa
authors: Masayoshi
authors: M
authors: Kobune
authors: Rishu
authors: R
authors: Takimoto
authors: Junji
authors: J
authors: Kato
authors: Yoshiro
authors: Y
authors: Niitsu
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004279:DNA, Viral / Q000032:analysis; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006509:Hepatitis B / Q000821:virology*; D006515:Hepatitis B virus / Q000502:physiology*; D006801:Humans; D016899:Interferon-beta / Q000627:therapeutic use; D019259:Lamivudine / Q000008:administration & dosage / Q000627:therapeutic use*; D016393:Lymphoma, B-Cell / Q000188:drug therapy* / Q000821:virology; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D000069283:Rituximab; D014750:Vincristine / Q000627:therapeutic use; D014775:Virus Activation / Q000187:drug effects*
chemical_list: D019380:Anti-HIV Agents; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D004279:DNA, Viral; D019259:Lamivudine; D000069283:Rituximab; D014750:Vincristine; D016899:Interferon-beta; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone